BioCryst Pharmaceuticals

Rare Disease. Real Barriers Removed.

  • Compliance

    WCAG 2.1 AA

    Compliance Achieved

  • Branded Site

    Pharma Marketing Website

  • Real Users

    Tested with Disabled Testers

The Challenge

BioCryst Pharmaceuticals is a global biotechnology company focused on developing innovative medicines for patients living with rare and serious diseases.

BioCryst Pharmaceuticals is a global biotechnology company focused on developing innovative medicines for patients living with rare and serious diseases. Their branded pharmaceutical marketing websites serve a patient population that is often small, highly engaged, and deeply dependent on digital resources for information about treatments that may represent their only therapeutic option.



For a rare disease company, the accessibility stakes of a branded website are amplified. Patients living with rare conditions — many of which involve physical, neurological, or sensory impairments — are statistically more likely to rely on assistive technologies to navigate the web. An inaccessible branded website doesn't just create ADA exposure for BioCryst; it shuts out the very patients the medicine was developed to help.



BioCryst's digital team recognized that accessibility couldn't be treated as an afterthought on a branded pharmaceutical site. They needed a partner who could deliver human-led audit expertise, verified remediation, and real-world validation — ensuring that every patient who needs this information can access it.

The Inclusive Web Solution

Inclusive Web conducted a focused human-led WCAG 2.1 AA audit of BioCryst's branded pharmaceutical marketing website, with particular sensitivity to the rare disease patient experience — evaluating how patients and caregivers navigate complex medical content, locate support resources, and access information about disease management and treatment.

Our team worked closely with BioCryst's digital and medical affairs teams to develop a remediation roadmap that balanced accessibility compliance with the regulatory requirements of pharmaceutical content. Every fix was verified before sign-off, and the final experience was validated by real users who identify as disabled.

  • Human-led WCAG 2.1 AA audit of the full branded pharmaceutical marketing website

  • Rare disease patient and caregiver journey audit — disease information, treatment details, safety data, and patient support resources

  • Accessibility review of pharmaceutical content components including safety disclosures, patient enrollment flows, and medical content navigation

  • Remediation approach designed to work within pharmaceutical regulatory content requirements

  • Prioritized roadmap with sensitivity to the small, highly engaged rare disease patient audience

  • Fix verification — every resolved issue confirmed working before sign-off

  • Real-user testing with testers who identify as disabled, validating the rare disease patient experience using screen readers, keyboard navigation, and voice control

  • Ongoing monitoring to maintain compliance through regulatory content updates and disease awareness campaigns

Real-User Accessibility Testing — When Health Information Must Be Accessible to All

Inclusive Web validated BioCryst Pharmaceuticals's branded pharmaceutical website with testers who identify as disabled and rely on assistive technologies daily — including screen readers (JAWS, NVDA, VoiceOver), keyboard-only navigation, and voice control. In healthcare, this means ensuring that patients, caregivers, and healthcare professionals who need information about a treatment can access it fully and independently — regardless of ability.

The Result

WCAG 2.1 AA compliance achieved across the BioCryst branded pharmaceutical marketing website

All rare disease patient and caregiver-facing content — including treatment information, safety data, and patient support enrollment — made fully accessible

Pharmaceutical content components including safety disclosures and patient enrollment flows accessible to users relying on assistive technologies

WCAG 2.1 AA compliance achieved across all three digital properties — visitor website, Ellis Island museum digital experience, and mobile visitor app

Real-user testing confirmed that rare disease patients and caregivers with disabilities can access the information they need with full independence

BioCryst's branded digital presence now reflects the company's commitment to every patient living with the rare conditions it works to treat

Ongoing monitoring in place to protect compliance through the regulatory content lifecycle

"Patients living with rare diseases depend on digital access for critical treatment information. BioCryst’s platform needed to serve everyone equally. Inclusive Web ensured no patient was left behind."

BIOCRYST PHARMACEUTICALS – RARE DISEASE ACCESSIBILITY CASE STUDY

Services Delivered

WCAG 2.1 AA Audit (Branded Pharma Website)

Remediation Verification

Rare Disease Patient Journey Audit

Real-User Usability Testing

Pharmaceutical Content & Safety Disclosure Review

Ongoing Accessibility Monitoring

Compliance & Regulatory Drivers

Federal obligations and public expectations that made this work essential.

ADA Title III Legal Risk Mitigation

WCAG 2.1 AA Compliance

Rare Disease Patient Equity Mission

Pharmaceutical Content Compliance

Is your rare disease brand website accessible to every patient who depends on it?

Inclusive Web helps pharmaceutical and healthcare companies ensure their branded digital properties are accessible to every patient, caregiver, and healthcare professional who depends on them.

Get Your Accessibility Assessment